Charles Schwab Investment Management Inc Theseus Pharmaceuticals, Inc. Transaction History

Charles Schwab Investment Management Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	BUY	$7.28 - $11.82 $80,749 - $131,107	11,092 Added 24.59%	56,203 $524,000
Q1 2023 May 11, 2023	BUY	$5.21 - $14.05 $9,294 - $25,065	1,784 Added 4.12%	45,111 $400,000
Q2 2022 Aug 15, 2022	BUY	$5.04 - $14.05 $55,933 - $155,926	11,098 Added 34.43%	43,327 $240,000
Q1 2022 May 13, 2022	BUY	$8.75 - $14.51 $11,243 - $18,645	1,285 Added 4.15%	32,229 $372,000
Q4 2021 Feb 11, 2022	BUY	$8.98 - $20.09 $277,877 - $621,664	30,944 New	30,944 $393,000

1.03M

Ticker THRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,713,400
Description
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also ...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.